Microsleep

Last updated
Example of an EEG alpha wave Eeg alpha.svg
Example of an EEG alpha wave
Example of an EEG theta wave Eeg theta.svg
Example of an EEG theta wave

A microsleep is a sudden temporary episode of sleep or drowsiness which may last for a few seconds where an individual fails to respond to some arbitrary sensory input and becomes unconscious. [1] [2] Episodes of microsleep occur when an individual loses and regains awareness after a brief lapse in consciousness, often without warning, or when there are sudden shifts between states of wakefulness and sleep. In behavioural terms, MSs may manifest as droopy eyes, slow eyelid-closure, and head nodding. [2] In electrical terms, microsleeps are often classified as a shift in electroencephalography (EEG) during which 4–7 Hz (theta wave) activity replaces the waking 8–13 Hz (alpha wave) background rhythm. [3]

Contents

Definition

Some experts define microsleep according to behavioral criteria (head nods, drooping eyelids, etc.), while others rely on EEG markers. [4] Since there are many ways to detect MSs in a variety of contexts there is little agreement on how best to identify and classify microsleep episodes.

Causes

MSs frequently occur as a result of sleep deprivation. [5] However, individuals who are not sleep-deprived or tired can also experience MSs during monotonous tasks. [6] [7] [8] [9] [10]

Effects

Microsleep is extremely dangerous when it occurs in situations that demand constant alertness, such as driving a motor vehicle or working with heavy machinery. People who experience microsleeps often remain unaware of them, instead believing themselves to have been awake the whole time, or to have temporarily lost focus. [11]

Background and significance

Eyelid closed, demonstrating microsleep event according to eye-video test Microsleep.png
Eyelid closed, demonstrating microsleep event according to eye-video test
Traffic collision, a possible consequence of microsleep LKW Auffahrunfall 16122008 1.jpg
Traffic collision, a possible consequence of microsleep

With over 1,550 fatalities and 40,000 nonfatal injuries occurring annually in the United States alone as a result of drowsy driving, sleep loss has become a public health problem. [12] [13] When experiencing microsleeps while driving an automobile, from the perspective of the driver, they are driving a car, and then suddenly realize that several seconds have passed by unnoticed. It is not obvious to the driver that they were asleep during those missing seconds, although this is in fact what happened. [14] The sleeping driver is at very high risk for having a collision during a microsleep episode. [15]

Historically, many accidents and catastrophes have resulted from microsleep episodes in these circumstances. [16] For example, a microsleep episode is claimed to have been one factor contributing to the Waterfall rail accident in 2003; the driver had a heart attack, and the guard who should have reacted to the train's increasing speed is said by his defender to have microslept, thus causing him to be held unaccountable. On May 31, 2009, an Air France plane (Air France Flight 447) carrying 228 people from Brazil to France crashed into the Atlantic Ocean, killing everyone on board. The pilot of the plane reported "I didn't sleep enough last night. One hour – it's not enough," handing over control to the two co-pilots who did not respond appropriately when the plane was in distress. [17] A possible microsleep was recorded as part of the narrative verdict in the inquest into the 2016 Croydon tram derailment. [18]

Thus, microsleeps are often examined in the context of driver drowsiness detection and prevention of work-related injuries and public safety incidents (e.g. truck crashes, locomotive crashes, airplane crashes, etc.). Some statistics are below:

The 2016 Croydon tram derailment, a result of a suspected microsleep afflicting the driver Sandilands Junction derailed tram.jpg
The 2016 Croydon tram derailment, a result of a suspected microsleep afflicting the driver

Microsleep episodes are not dangerous in and of themselves, however. The only risk that comes is from the potential that they carry to cause incidents resulting from lack of awareness. If an individual has occurrences of microsleep in an environment that is free from potential environmental risk and its associated consequences, then episodes of microsleep should be non-problematic. [14]

Neural correlates

Generally, microsleeps are characterized by a decrease in activity in wakefulness-related regions of the brain and an increase in activity in sleep-related regions of the brain. Looking at neural correlates of microsleeps is difficult because microsleeps can also be triggered by monotonous tasks (e.g. such as driving or dozing off in class). Therefore, it is important to examine neural correlates of microsleep events with respect to experimental set-ups (e.g. simulated driving set-up, reaction time set-up, etc.). Individual variability in brain structure also makes it difficult to diagnose microsleep events objectively. [24] [ verification needed ]

In one study neural activity underlying MSs was investigated by simultaneously measuring eye video, response behavior, EEG, and fMRI in normally-rested individuals engaged in a sensory-motor task. [2] Twenty participants tracked a visual stimulus with a joystick for 50 minutes in 2 dimensions (up/down/right/left) on a computer screen. Participants performed this task in an fMRI scanner such that joystick response, right eye-video, EEG (60 EEG electrodes), and fMRI data were recorded simultaneously. Most participants had frequent microsleeps (>35) in a continuous visuomotor task (tracking visual stimulus on a screen), corresponding with decreased activity in arousal-related brain regions over time (thalamus, midbrain, and the posterior cingulate cortex). [2]

Another study examined the activation patterns of 5 people who woke up from microsleeps in a simulated driving experiment. [10] It was found that upon awakening the visual area, frontal cortex, limbic lobe were activated (in the intense activation phase) and the frontal cortex, temporal cortex, primary motor area, and insula were activated (in the post abrupt awakening phase). Therefore, the study concluded that decision-making was not activated immediately upon waking up from a MS episode, likely increasing risk of injury in intense decision-making tasks like driving or surgery.

The transition from wakefulness to sleep is regulated by a variety of chemicals. Adenosine likely causes the 'feeling sleepy' side of microsleeps, while dopamine likely reduces microsleep events by promoting wakefulness. It has been shown that microsleeps correlate with spontaneous pontine-geniculate-occipital (PGO waves) waves, which suppress visual processing in the basal ganglia. When this pathway is not activated, cells in the superior colliculus (which causes release of dopamine) cannot be dis-inhibited via the basal ganglia, leading to poor processing ability and microsleep onset. [25]

Detection methods and classifications

There are currently many ways to detect microsleeps; however, there is a lack of general consensus as to the best way to identify and classify microsleeps. The simplest methods to detect these events seem to be through psychological tests, speech tests, and behavioral tests (e.g. yawn test and eye-video test). More complex and expensive ways to detect microsleeps include EEG, fMRI, EOG, and PSG tied to various software platforms. When multiple tests are used in parallel, detection of microsleeps most likely will become more accurate. [2]

MethodDescription or examples
Polysomnography (PSG)PSG monitors many body functions including brain (EEG), eye movements (EOG), muscle activity or skeletal muscle activation (EMG) and heart rhythm (ECG) during sleep.
Electroencephalography (EEG)EEG records the brain's spontaneous electrical activity over a short period of time, usually 20–40 minutes, as recorded from multiple electrodes on the scalp. [26] Microsleeps have EEG shift to slower frequencies (from alpha to theta waves). [27]
Functional magnetic resonance imaging (fMRI)A functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow (detects what regions of brain are active during microsleep events). [28]
Psychological tests Reaction time test, Karolinska Sleepiness Scale (KSS), [29] Maintenance of Wakefulness Test (MWT), [30] Multiple Sleep Latency Test (MSLT). [31]
Electrooculogram (EOG)EOG is a technique for measuring the resting potential of the retina in the human eye. [32]
Eye-video testMeasures eyes blinking and eye movements to detect microsleep events. [33] [34]
Mouth yawning testCounts number of yawns over a period of time. [35]
Speech testsExamines emotions and/or prosody in speech to predict microsleep episodes. [29] [36] [37]

Despite attempts to globally classify microsleeps through these detection methods (with particular emphasis on EEG and slow eyelid closure tests), there is great variability in the types of microsleeps that people experience. [38] Subjective, self-reported psychological tests like the Karolinska Sleepiness Scale (KSS), though widely adopted and positively correlated to EEG, often have limited utility because individuals sometimes are not aware of their level of sleepiness. [39] Future research needs to focus more on objective microstates (e.g. detailed electrical output in briefer intervals) that underlie microsleep events so that electrical events can be understood in terms of behavioral events with greater accuracy. [40] Then microsleep events could be more seamlessly distinguished from other states of consciousness, such as silent consciousness experienced during meditation. [41]

Disorders, clinical studies, and pharmacology

Microsleeps are often tied to disorders. Sleep apnea is by far the most significant disease tied to microsleeps in terms of prevalence, affecting roughly 10–15 million people. [42] Other disorders that may be tied to microsleeps include narcolepsy, hypersomnia, schizophrenia, and other causes of excessive daytime sleepiness. Microsleep episodes are often neglected and are not used as a diagnostic indicator for these disorders. Instead, clinicians use instrumentation like PSG to do a sleep study on patients to assess overall sleep quality in a laboratory setting. [43]

Microsleeps that recur and negatively influence day-to-day living often are clustered into the category of excessive daytime sleepiness. Thus, most clinical studies related to microsleeps are in the context of reducing microsleeps in excessive daytime sleepiness through the use of pharmacological interventions. Particularly, modafinil has become a popular drug to reduce microsleeps due to its eugeroic effect with comparatively mild side effects relative to classical psychostimulants. New drugs are often compared to the results of modafinil and placebo to assess efficacy (e.g. methylphenidate in Parkinson's Disease). Modafinil is also being tested across a range of disorders such as schizophrenia, narcolepsy, cataplexy, and sleep apnea. Overall, the trajectory of clinical studies relating to negative symptom microsleeps seems to more thoroughly test modafinil across more disorders and compare new drugs to the efficacy of modafinil to reduce the negative effects of microsleeps on people across a spectrum of disorders.

TitleInterventionsConditions
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. [44] Drug: BF2.649, Drug: Modafinil, Drug: PlaceboTreatment of Excessive Daytime Sleepiness in Narcolepsy.
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy [45] Drug: BF2.649, Modafinil, Placebo Narcolepsy, Excessive Daytime Sleepiness, Cataplexy, Sleep Disorders
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients [46] Drug: Placebo, Drug: BF 2.649 5 mg, Drug: BF 2.649 10 mg, Drug: BF 2.649 20 mg, Drug: BF 2.649 40 mgExcessive Daytime Sleepiness, Parkinson's disease
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy [47] Drug: Placebo, Drug: PF-03654746Excessive Daytime Sleepiness, Narcolepsy
Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) [48] Comparator: MK0249, Drug: Comparator: placebo, Drug: Comparator: modafinilSleep Apnea (Obstructive), Hypopnea Syndrome, Excessive Daytime Sleepiness
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) [49] Drug: Pitolisant, Drug: PlaceboNarcolepsy with Cataplexy, Excessive Daytime Sleepiness
Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease [50] Drug: modafinil, Drug: methylphenidate Parkinson's Disease
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia [51] Drug: Modafinil, Drug: PlaceboSchizophrenia
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease [52] Drug: BF2.649 (Pitolisant)Parkinson's Disease
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) [53] Drug: sodium oxybate Parkinson's Disease

Microsleeps sometimes are a side effect of various drugs, particularly in reference to dopamine-stimulating drugs in Parkinson's Disease. Particularly, somnolence is a recognized adverse effect of dopamine agonists, pramipexole and ropinirole. These drugs are known to cause sudden-onset sleep spells in roughly 50% of patients with Parkinson's disease (PD) while they were driving. [54] Therefore, clinical interventions pertaining to microsleeps may also encompass reducing excessive sleepiness as a side effect of drug administration. Orexin antagonists such as daridorexant and suvorexant may cause hypersomnolence and microsleeps.

Most microsleeps are not clinically significant, however. Individuals who feel sleepy and wish to maintain alertness often consume over-the-counter stimulants such as caffeine in coffee. More specifically, it has been shown that high-frequency low-dose caffeine intake is effective at countering poor work performance effects due to extended wakefulness, confirming the hypothesis that adenosine is a mediator of performance decrements associated with extended wakefulness. [55] Other stimulants that could decrease microsleep frequency include Adderall, amphetamine, cocaine, and tobacco. [56] [57]

See also

Related Research Articles

<span class="mw-page-title-main">Modafinil</span> Eugeroic medication

Modafinil, sold under the brand name Provigil among others, is a wakefulness-promoting medication used primarily to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. Modafinil is also approved for stimulating wakefulness in people with sleep apnea and shift work sleep disorder. It is taken by mouth. Modafinil is not approved by the US Food and Drug Administration (FDA) for use in people under 17 years old.

<span class="mw-page-title-main">Sleep disorder</span> Medical disorder of a persons sleep patterns

A sleep disorder, or somnipathy, is a medical disorder of an individual's sleep patterns. Some sleep disorders are severe enough to interfere with normal physical, mental, social and emotional functioning. Sleep disorders are frequent and can have serious consequences on patients' health and quality of life. Polysomnography and actigraphy are tests commonly ordered for diagnosing sleep disorders.

Dyssomnias are a broad classification of sleeping disorders involving difficulty getting to sleep, remaining asleep, or of excessive sleepiness.

Somnolence is a state of strong desire for sleep, or sleeping for unusually long periods. It has distinct meanings and causes. It can refer to the usual state preceding falling asleep, the condition of being in a drowsy state due to circadian rhythm disorders, or a symptom of other health problems. It can be accompanied by lethargy, weakness and lack of mental agility.

Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes and can cause distress and problems with functioning. In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), hypersomnolence, of which there are several subtypes, appears under sleep-wake disorders.

<span class="mw-page-title-main">Polysomnography</span> Multi-parameter study of sleep and sleep disorders

Polysomnography (PSG) is a multi-parameter type of sleep study and a diagnostic tool in sleep medicine. The test result is called a polysomnogram, also abbreviated PSG. The name is derived from Greek and Latin roots: the Greek πολύς, the Latin somnus ("sleep"), and the Greek γράφειν.

<span class="mw-page-title-main">Obstructive sleep apnea</span> Sleeping and breathing disorder

Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is characterized by recurrent episodes of complete or partial obstruction of the upper airway leading to reduced or absent breathing during sleep. These episodes are termed "apneas" with complete or near-complete cessation of breathing, or "hypopneas" when the reduction in breathing is partial. In either case, a fall in blood oxygen saturation, a disruption in sleep, or both, may result. A high frequency of apneas or hypopneas during sleep may interfere with the quality of sleep, which – in combination with disturbances in blood oxygenation – is thought to contribute to negative consequences to health and quality of life. The terms obstructive sleep apnea syndrome (OSAS) or obstructive sleep apnea–hypopnea syndrome (OSAHS) may be used to refer to OSA when it is associated with symptoms during the daytime.

<span class="mw-page-title-main">Somnology</span> Scientific study of sleep

Somnology is the scientific study of sleep. It includes clinical study and treatment of sleep disorders and irregularities. Sleep medicine is a subset of somnology.

<span class="mw-page-title-main">Armodafinil</span> Eugeroic medication

Armodafinil, sold under the brand name Nuvigil, is a wakefulness-promoting medication which is used to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and shift work disorder. It is also used off-label for certain other indications. The drug is taken by mouth.

The Multiple Sleep Latency Test (MSLT) is a sleep disorder diagnostic tool. It is used to measure the time elapsed from the start of a daytime nap period to the first signs of sleep, called sleep latency. The test is based on the idea that the sleepier people are, the faster they will fall asleep.

The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness that is measured by use of a very short questionnaire. This can be helpful in diagnosing sleep disorders. It was introduced in 1991 by Dr Murray Johns of Epworth Hospital in Melbourne, Australia.

Excessive daytime sleepiness (EDS) is characterized by persistent sleepiness and often a general lack of energy, even during the day after apparently adequate or even prolonged nighttime sleep. EDS can be considered as a broad condition encompassing several sleep disorders where increased sleep is a symptom, or as a symptom of another underlying disorder like narcolepsy, circadian rhythm sleep disorder, sleep apnea or idiopathic hypersomnia.

<span class="mw-page-title-main">Sleep medicine</span> Medical specialty devoted to the diagnosis and therapy of sleep disturbances and disorders

Sleep medicine is a medical specialty or subspecialty devoted to the diagnosis and therapy of sleep disturbances and disorders. From the middle of the 20th century, research has provided increasing knowledge of, and answered many questions about, sleep–wake functioning. The rapidly evolving field has become a recognized medical subspecialty in some countries. Dental sleep medicine also qualifies for board certification in some countries. Properly organized, minimum 12-month, postgraduate training programs are still being defined in the United States. In some countries, the sleep researchers and the physicians who treat patients may be the same people.

<span class="mw-page-title-main">Narcolepsy</span> Human sleep disorder

Narcolepsy is a chronic neurological disorder that impairs the ability to regulate sleep–wake cycles, and specifically impacts REM sleep. The pentad symptoms of narcolepsy include excessive daytime sleepiness (EDS), sleep-related hallucinations, sleep paralysis, disturbed nocturnal sleep (DNS), and cataplexy. People with narcolepsy tend to sleep about the same number of hours per day as people without it, but the quality of sleep is typically compromised.

Pitolisant, sold under the brand name Wakix among others, is a medication used for the treatment of excessive daytime sleepiness in adults with narcolepsy. It is an inverse agonist of the histamine 3 (H3) receptor (an antihistamine drug specific to that kind of receptors). It represents the first commercially available medication in its class, so that the U.S. Food and Drug Administration (FDA) declares it a first-in-class medication. Pitolisant enhances the activity of histaminergic neurons in the brain that function to improve a person's wakefulness. It was approved by the European Medicines Agency (EMA) in March 2016 for narcolepsy with or without cataplexy, and for excessive daytime sleepiness by the FDA in August 2019. The most common side effects include difficulty sleeping, nausea, and feeling worried.

<span class="mw-page-title-main">Eugeroic</span> Drug for wakefulness and alertness

A eugeroic, or eugregoric, also known as a vigilance-promoting agent, is a type of drug that increases vigilance. The term has been used inconsistently and in multiple ways in the scientific literature, either to refer specifically to modafinil-type wakefulness-promoting agents or to refer to wakefulness-promoting agents generally. It was first introduced in the French literature in 1987 as a descriptor for modafinil-like wakefulness-promoting drugs and for purposes of distinguishing such drugs from psychostimulants. However, the term "eugeroic" has not been widely adopted in the literature, and instead the term "wakefulness-promoting agent" has been more widely used, both for modafinil-type drugs and other agents.

Idiopathic hypersomnia(IH) is a neurological disorder which is characterized primarily by excessive sleep and excessive daytime sleepiness (EDS). Idiopathic hypersomnia was first described by Bedrich Roth in 1976, and it can be divided into two forms: polysymptomatic and monosymptomatic. The condition typically becomes evident in early adulthood and most patients diagnosed with IH will have had the disorder for many years prior to their diagnosis. As of August 2021, an FDA-approved medication exists for IH called Xywav, which is an oral solution of calcium, magnesium, potassium, and sodium oxybates; in addition to several off-label treatments (primarily FDA-approved narcolepsy medications).

<span class="mw-page-title-main">Wakefulness-promoting agent</span> Drug that increases wakefulness

A wakefulness-promoting agent (WPA), or wake-promoting agent, is a drug that increases wakefulness and arousal. They are similar to but distinct from psychostimulants, which not only promote wakefulness but also produce other more overt central nervous system effects, such as improved mood, energy, and motivation. Wakefulness-promoting agents are used to treat narcolepsy and hypersomnia as well as to promote wakefulness and increase performance in healthy people.

<span class="mw-page-title-main">Flmodafinil</span> Wakefulness-promoting drug/Dopamine reuptake inhibitor

Flmodafinil, also known as bisfluoromodafinil and lauflumide, is a wakefulness-promoting agent related to modafinil which has been developed for treatment of a variety of different medical conditions. These include chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease. Aside its development as a potential pharmaceutical drug, flmodafinil is sold online and used non-medically as a nootropic.

<span class="mw-page-title-main">Solriamfetol</span> Medication used for the treatment of excessive sleepiness

Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.

References

Citations

  1. ↑ International Classification of Sleep Disorders, Diagnostic and Coding Manual (PDF). Archived from the original (PDF) on 2011-07-26. Retrieved 2011-07-26., page 343
  2. 1 2 3 4 5 Poudel, G. R., Innes, C. R., Bones, P. J., Watts, R., & Jones, R. D. (2012) Losing the struggle to stay awake: Divergent thalamic and cortical activity during microsleeps. Human Brain Mapping: 00:000-000
  3. ↑ Paul, Amit; Linda Ng Boyle; Jon Tippin; Matthew Rizzo (2005). "Variability of driving performance during microsleeps" (PDF). Proceedings of the Third International Driving Symposium on Human Factors in Driver Assessment, Training and Vehicle Design. Archived from the original (PDF) on 2014-10-09. Retrieved 2008-02-10.
  4. ↑ Poudel, G.R.; Innes, C. R. H.; Bones, P.J.; Watts, R.; Jones, R. D. (2014). "Losing the struggle to stay awake: divergent thalamic and cortical activity during microsleeps" (PDF). Human Brain Mapping. 35 (1): 257–269. doi:10.1002/hbm.22178. PMC   6869765 . PMID   23008180. Archived from the original (PDF) on 2014-03-31. Retrieved 2013-03-20.
  5. ↑ "What You Should Know About Microsleep".
  6. ↑ Poudel, GR; Innes, CR; Bones, PJ; Watts, R; Jones, RD (January 2014). "Losing the struggle to stay awake: divergent thalamic and cortical activity during microsleeps". Human Brain Mapping. 35 (1): 257–69. doi:10.1002/hbm.22178. PMC   6869765 . PMID   23008180.
  7. ↑ Moller, Henry J.; Kayumov, Leonid; Bulmash, Eric L.; Nhan, Jonathan; Shapiro, Colin M. (September 2006). "Simulator performance, microsleep episodes, and subjective sleepiness: normative data using convergent methodologies to assess driver drowsiness". Journal of Psychosomatic Research. 61 (3): 335–342. doi:10.1016/j.jpsychores.2006.04.007. PMID   16938511.
  8. ↑ Peiris, Malik T. R.; Jones, Richard D.; Davidson, Paul R.; Carroll, Grant J.; Bones, Philip J. (September 2006). "Frequent lapses of responsiveness during an extended visuomotor tracking task in non-sleep-deprived subjects". Journal of Sleep Research. 15 (3): 291–300. doi:10.1111/j.1365-2869.2006.00545.x. PMID   16911031. S2CID   4667760.
  9. ↑ Innes, Carrie; R Poudel, Govinda; Signal, T.; Jones, Richard (2010). "Behavioural microsleeps in normally-rested people". 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology. Vol. 2010. pp. 4448–51. doi:10.1109/IEMBS.2010.5625953. ISBN   978-1-4244-4123-5. PMID   21095768. S2CID   12213583.
  10. 1 2 Chou, Y. H., Chuang, C. C., Zao, J. K., Ko, L. W., & Lin, C. T. (2011, August). An fMRI study of abrupt-awake episodes during behavioral microsleeps. In Engineering in Medicine and Biology Society, EMBC, 2011 Annual International Conference of the IEEE (pp. 5060-5063). IEEE.
  11. ↑ Higgins, Laura; Fette Bernie. "Drowsy Driving" (PDF). Archived from the original (PDF) on 2011-08-20. Retrieved 2013-06-12.
  12. 1 2 Insufficient Sleep Is a Public Health Epidemic. https://www.cdc.gov/features/dssleep/
  13. ↑ US Department of Transportation, National Highway Traffic Safety Administration, National Center on Sleep Disorders Research, National Heart Lung and Blood Institute. Drowsy driving and automobile crashes [National Highway Traffic Safety Administration Web Site]. Available at http://www.nhtsa.gov/people/injury/drowsy_driving1/Drowsy.html#NCSDR/NHTSAExternal Web Site Icon Accessed February 10, 2011.
  14. 1 2 "Microsleep: Symptoms, Causes, and Safety Risks". Sleep Foundation. 2021-08-26. Retrieved 2022-06-28.
  15. ↑ You, Chuang-Wen; Lane, Nicholas D.; Chen, Fanglin; Wang, Rui; Chen, Zhenyu; Bao, Thomas J.; Montes-de-Oca, Martha; Cheng, Yuting; Lin, Mu; Torresani, Lorenzo; Campbell, Andrew T. (June 25–28, 2013). CarSafe app: alerting drowsy and distracted drivers using dual cameras on smartphones. International Conference on Mobile Systems, Applications, and Services. p. 14. doi:10.1145/2462456.2465428.
  16. ↑ Blaivas AJ, Patel R, Hom D, Antigua K, Ashtyani H (2007). "Quantifying microsleep to help assess subjective sleepiness". Sleep Medicine Reviews . 8 (2): 156–9. doi:10.1016/j.sleep.2006.06.011. PMID   17239659.
  17. ↑ BEA final report, section 1.5, page 24 (PDF page 26 of 224): "The crew had left Paris on Thursday 28 May 2009 in the morning and arrived in Rio de Janeiro in the evening of the same day"
  18. ↑ "Croydon tram crash deaths were accidental, inquest rules". the Guardian. 22 July 2021. Retrieved 2021-07-23.
  19. ↑ Åkerstedt, T., Hallvig, D., Anund, A., Fors, C., Schwarz, J., & Kecklund, G. (2013). "Having to stop driving at night because of dangerous sleepiness–awareness, physiology and behaviour." Journal of Sleep Research.
  20. ↑ Sirois, B., Trutschel, U., Edwards, D., Sommer, D., & Golz, M. (2010, January). "Predicting Accident Probability from Frequency of Microsleep Events." In World Congress on Medical Physics and Biomedical Engineering, September 7–12, 2009, Munich, Germany (pp. 2284–2286). Springer Berlin Heidelberg.
  21. ↑ Swanson, L. M., ARNEDT, J., Rosekind, M. R., Belenky, G., Balkin, T. J., & Drake, C. (2011). "Sleep disorders and work performance: findings from the 2008 National Sleep Foundation Sleep in America poll." Journal of Sleep Research, 20(3), 487-494.
  22. ↑ National Highway Traffic Safety Administration. Traffic Safety Facts Crash Stats: Drowsy Driving. Washington, DC: DOT; 2011. DOT HS 811 4492011.
  23. ↑ "Pilot fatigue is like 'having too much to drink'." CNN, May 15, 2009. http://www.cnn.com/2009/TRAVEL/05/15/pilot.fatigue.buffalo.crash/
  24. ↑ Oken, B.S.; Salinsky, M.C.; Elsas, S.M. (September 2006). "Vigilance, alertness, or sustained attention: physiological basis and measurement". Clinical Neurophysiology . 117 (9): 1885–1901. doi:10.1016/j.clinph.2006.01.017. PMC   2865224 . PMID   16581292.
  25. ↑ Silkis, I. G. (2010). Analysis of the effects of neuromodulators on the generation of spontaneous pontine-geniculate-occipital (PGO) waves. Neurochemical Journal, 4(3), 170-177.
  26. ↑ Davidson, P. R., Jones, R. D., & Peiris, M. T. R. (2006, January). Detecting Behavioral Microsleeps using EEG and LSTM Recurrent Neural Networks. InEngineering in Medicine and Biology Society, 2005. IEEE-EMBS 2005. 27th Annual International Conference of the (pp. 5754-5757). IEEE.
  27. ↑ Boyle, L. N., Tippin, J., Paul, A., & Rizzo, M. (2008). Driver performance in the moments surrounding a microsleep. Transportation research part F: traffic psychology and behaviour, 11(2), 126-136.
  28. ↑ Chou, Y. H., Chuang, C. C., Zao, J. K., Ko, L. W., & Lin, C. T. (2011, August). An fMRI study of abrupt-awake episodes during behavioral microsleeps. InEngineering in Medicine and Biology Society, EMBC, 2011 Annual International Conference of the IEEE (pp. 5060-5063). IEEE.
  29. 1 2 Krajewski, J., Wieland, R., & Batliner, A. (2008). An acoustic framework for detecting fatigue in speech based Human-Computer-Interaction. In Computers Helping People with Special Needs (pp. 54-61). Springer Berlin Heidelberg.
  30. ↑ Gast, H., Schindler, K., Rummel, C., Herrmann, U. S., Roth, C., Hess, C. W., & Mathis, J. (2011). EEG correlation and power during maintenance of wakefulness test after sleep-deprivation. Clinical Neurophysiology, 122(10), 2025-2031.
  31. ↑ Blaivas, A. J., Patel, R., Hom, D., Antigua, K., & Ashtyani, H. (2007). Quantifying microsleep to help assess subjective sleepiness. Sleep Medicine Reviews,8(2), 156-159.
  32. ↑ Sommer, D., Chen, M., Golz, M., Trutschel, U., & Mandic, D. (2005). Fusion of state space and frequency-domain features for improved microsleep detection. In Artificial Neural Networks: Formal Models and Their Applications–ICANN 2005 (pp. 753-759). Springer Berlin Heidelberg.
  33. ↑ Poudel, G. R., Innes, C. R., Bones, P. J., & Jones, R. D. (2010, August). The relationship between behavioural microsleeps, visuomotor performance and EEG theta. In Engineering in Medicine and Biology Society (EMBC), 2010 Annual International Conference of the IEEE (pp. 4452-4455). IEEE.
  34. ↑ Malla, A. M., Davidson, P. R., Bones, P. J., Green, R., & Jones, R. D. (2010, August). Automated video-based measurement of eye closure for detecting behavioral microsleep. In Engineering in Medicine and Biology Society (EMBC), 2010 Annual International Conference of the IEEE (pp. 6741-6744). IEEE.
  35. ↑ Noor, H. A. M., & Ibrahim, R. (2010). Fatigue detector using eyelid blinking and mouth yawning. In Computer Vision and Graphics (pp. 134-141). Springer Berlin Heidelberg.
  36. ↑ Krajewski, J., Batliner, A., & Wieland, R. (2008, December). Multiple classifier applied on predicting microsleep from speech. In Pattern Recognition, 2008. ICPR 2008. 19th International Conference on (pp. 1-4). IEEE.
  37. ↑ Krajewski, J., Golz, M., Sommer, D., & Wieland, R. (2009, January). Genetic algorithm based feature selection applied on predicting microsleep from speech. In 4th European Conference of the International Federation for Medical and Biological Engineering (pp. 184-187). Springer Berlin Heidelberg.
  38. ↑ Galley, N., Schleicher, R., & Galley, L. (2003). Oculomotor Indicators of Driver Fatigue. Driver Behaviour and Training: v. III, 1, 97.
  39. ↑ Shahid, A., Wilkinson, K., & Marcu, S. (2012). Karolinska Sleepiness Scale (KSS). In STOP, THAT and One Hundred Other Sleep Scales (pp. 209-210). Springer New York.
  40. ↑ Cvetkovic, D., & Cosic, I. (2011). Sleep Onset Process as an Altered State of Consciousness. In States of Consciousness (pp. 157-185). Springer Berlin Heidelberg.
  41. ↑ Baars, B. J. (2013). A scientific approach to silent consciousness. Frontiers in Psychology, 4.
  42. ↑ Kanagala, R., Murali, N. S., Friedman, P. A., Ammash, N. M., Gersh, B. J., Ballman, K. V., ... & Somers, V. K. (2003). Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation, 107(20), 2589-2594.
  43. ↑ Tufik, S., Santos-Silva, R., Taddei, J. A., & Bittencourt, L. R. A. (2010). Obstructive sleep apnea syndrome in the Sao Paulo epidemiologic sleep study. Sleep Medicine Reviews, 11(5), 441-446.
  44. ↑ Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. http://clinicaltrials.gov/ct2/show/record/NCT01638403
  45. ↑ Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. http://ClinicalTrials.gov/show/NCT01067222
  46. ↑ Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients . http://ClinicalTrials.gov/show/NCT00642928
  47. ↑ A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy. http://ClinicalTrials.gov/show/NCT01006122
  48. ↑ Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015). http://ClinicalTrials.gov/show/NCT00620659
  49. ↑ Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP). http://ClinicalTrials.gov/show/NCT01800045
  50. ↑ Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease. http://ClinicalTrials.gov/show/NCT00393562
  51. ↑ Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia . http://ClinicalTrials.gov/show/NCT00546403
  52. ↑ Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease. http://ClinicalTrials.gov/show/NCT01066442
  53. ↑ Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD). http://ClinicalTrials.gov/show/NCT00641186
  54. ↑ Hobson, D. E., Lang, A. E., Martin, W. W., Razmy, A., Rivest, J., & Fleming, J. (2002). "Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. "JAMA: The Journal of the American Medical Association, 287(4), 455–463. Chicago
  55. ↑ Wyatt, J. K., Cajochen, C., Cecco, A. R. D., Czeisler, C. A., & Dijk, D. J. (2004). "Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness." SLEEP-NEW YORK THEN WESTCHESTER-, 27(3), 374–382.
  56. ↑ Jacobs, A. (2005). "The Adderall advantage." New York Times, 31.
  57. ↑ Gawin, F. H., & Ellinwood, E. H. (1988). "Cocaine and other stimulants: actions, abuse, and treatment." The New England Journal of Medicine.

Works cited

  • Ogilvie RD (June 2001). "The process of falling asleep". Sleep Med Rev. 5 (3): 247–270. doi:10.1053/smrv.2001.0145. PMID   12530990.
  • Tirunahari VL, Zaidi SA, Sharma R, Skurnick J, Ashtyani H (January 2003). "Microsleep and sleepiness: a comparison of multiple sleep latency test and scoring of microsleep as a diagnostic test for excessive daytime sleepiness". Sleep Med. Rev. 4 (1): 63–7. doi:10.1016/s1389-9457(02)00250-2. PMID   14592362.
  • Faber J, Novák M, Svoboda P, Tatarinov V, Tichý T (2003). "[Microsleep from the electro- and psychophysiological point of view]". Sb Lek (in Czech). 104 (4): 375–85. PMID   15320529.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.